INO Inovio Pharmaceuticals Inc

$INO We have a Market Cap of $100M and just won the lawsuit for $80M! That’s crazy! Release the news! 🎉🚀🔥

$INO Absolutely do not let anyone talk you out of your shares. 6.5 year lawsuit won. $80 million dollar decision made on behalf of Inovio. Who cares about collection. We won. Next stop fda Pdufa

$INO Preparing for a big run! Hold on to your shares! Either news of the lawsuit we just won or the FDA approval will see us running hard!! let’s go! 🚀🚀🚀

$INO Lengthy litigation with VGXI/Gene One is now done with the victory for INO. There will be $80M payable to INO from GeneOne/VGXI. Great news and I can't be happier. It has been a long one, for most of the longs here. The stock will only go up from here, IMO. GLT Longs as we all deserve this moment on. Very

$INO Ino3107 will most likely be approved by FDA on or before OCT 30th for the following reason: INO 3107 can be used to re dose as many times as needed for those who do not progress to CR. For those who use Precigen's treatments （PAPZIMEOS） if they do not progress to CR will need to resort to surgeries again or Avastin （bevacizumab） with side effects if ino3107 is not approved. The 24-month （Year 2） complete response (CR) rate for Precigen's Papzimeos drop from 51% in Year 1 to 43%（15 out of 35 patients） in Year2 while INO'S CR rate increased from 28 to 50% in year2. Major objection of FDA to refuse Inovio's AA pathway is for Inovio to show "meaningful clinical benefit " over PAPZIMEOS. Re dosing capability of ino3107 is a strong meaningful clinical benefit for RRP INO3107 retains the Breakthrough Therapy Designation up to this moment. Whether INOVIO gets compensation or not from the INO vs VGXI case is not that relevant to the approval of ino3107.

$INO Ongoing, lengthy litigation of uncertain outcome is a boat anchor. Now it's gone. Congrats Inovio. The phone may start ringing.

$INO Nobody knows for sure what the FDA will decide, but I honestly believe approval is coming. If the FDA had major concerns, I find it hard to believe we’d be sitting here just days before the decision without knowing. I could be wrong, but I’m betting on approval. 100% convinced! Let’s go, INO! 🚀🚀

$INO Another BULLISH close: 43,336 shares at $1.15, and at the high of the day. Have a nice weekend friends. Only 21 days until Christmas.

$INO Understand What Winning The VGXI Case Means To INOVIO.....Any Partnerships With Upfront $$$$$ Are Free To Move Forward Without Hesitancy....Shareholders I Believe Will See Multiple Deals Roll Out Along INOVIO's Pipeline.....In Addition INOVIO Is Awarded $80,000,000 In Damages....This Is A Major Validation Of INOVIO's Ownership Of Their Technology.....For INOVIO This Is A Big Moment To Celebrate And Great For The Future Of The Company!!!!!!!

$INO very excited about what’s to come. I actually think the FDA’s rare disease announcement yesterday is a positive sign. It shows the agency is recognizing that rare diseases need a different approach, especially when large clinical trials aren’t realistic. That doesn’t guarantee anything for INO, but I do think it signals a willingness to be more flexible when evaluating treatments for patients with limited options.

$INO We are entering the most important stretch in INOVIO’s history. The FDA has completed its major review meetings and inspections, INOVIO has presented its case for accelerated approval, and the company is preparing for a potential launch. The October 30 PDUFA date is almost here. FDA and INOVIO are working through the final regulatory details, including the confirmatory trial design and the label. If the FDA is comfortable with the totality of the data and agrees that INO-3107 provides a meaningful benefit for RRP patients, we could see approval before the official deadline. Approval with a post approval confirmatory trial would be a major win for INOVIO, because it would allow the company to move toward commercialization while continuing to generate additional data. My view is that the next two weeks will be a defining moment for INOVIO and potentially the beginning of an entirely new chapter for the company. Good luck to all the investors out there.

$INO The core of the thesis is the shift toward gene therapies, where the DNA molecule and electroporation (Cellectra) will ultimately establish their dominance through pure molecular physics. As opposed to the structural fragility and inflammatory/reactogenic responses seen with RNA (resulting from the need for complex lipid nanoparticles), the higher native stability of the DNA double helix offers much cleaner precision, dose control, and long-term safety for the patient. Beyond the daily noise, the transition toward code-based medicine is already a historical reality, and the stability of the DNA platform will inevitably claim its place on scientific merit.

$INO INOVIO WON....BIG JUDGEMENT....PARTNERSHIPS AND COLLABORATIONS WITH BIG $$$$ ON THE WAY.....$80,000,000 JUDGEMENT TO BE RECEIVED BY INOVIO.....ALL GREAT FOR INOVIO

$INO ino 3107 ultimately going to be first line in treating rrp patients and going to pave the way for pediatric applications

$INO We will be making history soon! First DNA medicine approved, and INO-3107 will change the lives of so many RRP patients. October 30 can’t come soon enough. Let’s go FDA!! 🚀🚀🙏

$INO Cancer interception using INO-5401 is in clinical trials for the BRCA-1 and BRCA-2 gene mutation for breast, pancreatic cancer, prostate cancer, and ovarian cancers. Congratulations Dr. Susan Domchek! We are anxiously awaiting the Phase 1 results.

$INO Even though official 4-year data is not yet published, the FDA is already fully informed about the long-term status of the 2020 patient cohort. During an informal clinical meeting, INOVIO presented the totality of its data directly to the FDA. This crucial exchange gave regulators a transparent view of the durable, multi-year benefits experienced by the very first patients. With the late-cycle review completed and pre-license inspections successfully finalized, both parties are now transitioning into label negotiations. This close alignment confirms that the FDA has all the up-to-date insights needed behind the scenes.

$INO The estimated cost and value of VGXI's new headquarters and manufacturing facility in Conroe, Texas, is $95 million.

$INO Don't be surprised when FDA appoves ino3107 without a confirmatory trial The path to an approval without a confirmatory trial, or an unexpected pivot to traditional approval, is supported by several factors: • Label Negotiations and Completed Review: • The "Totality of Data" Argument: In recent clinical meetings, Inovio has focused heavily on presenting the long-term, multi-year extension data. Showing that 86% of patients achieved surgery reduction and 50% needed zero surgeries by Year 2 provides a compelling clinical benefit argument that could persuade the FDA to bypass conditional restrictions. • Precedent and Unmet Need: With RRP being a devastating rare disease, the FDA faces pressure to ensure multiple treatment options exist, especially since Precigen's approval established a regulatory appetite for immunotherapies in this space. If the FDA decides Inovio's Year 2 and 3 data directly demonstrates absolute clinical benefit, they have the statutory authority to pivot.

$INO Hmmm…very interesting, INOVIO is updating their channel on YouTube. It states the following: “Channel update in progress, stay tuned as we work to refresh our content.” I’ve never seen that before on YouTube.